Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 127

1.

Type I interferon correlates with serological and clinical manifestations of SLE.

Dall'era MC, Cardarelli PM, Preston BT, Witte A, Davis JC Jr.

Ann Rheum Dis. 2005 Dec;64(12):1692-7. Epub 2005 Apr 20.

2.

Neutrophil Extracellular Trap Mitochondrial DNA and Its Autoantibody in Systemic Lupus Erythematosus and a Proof-of-Concept Trial of Metformin.

Wang H, Li T, Chen S, Gu Y, Ye S.

Arthritis Rheumatol. 2015 Dec;67(12):3190-200. doi: 10.1002/art.39296.

3.
4.

Activation of type I interferon system in systemic lupus erythematosus correlates with disease activity but not with antiretroviral antibodies.

Bengtsson AA, Sturfelt G, Truedsson L, Blomberg J, Alm G, Vallin H, Rönnblom L.

Lupus. 2000;9(9):664-71.

PMID:
11199920
5.

Serum ferritin level correlates with SLEDAI scores and renal involvement in SLE.

Tripathy R, Panda AK, Das BK.

Lupus. 2015 Jan;24(1):82-9. doi: 10.1177/0961203314552290. Epub 2014 Sep 24.

PMID:
25253568
6.

Anti-C1q antibodies and antiendothelial cell antibodies in systemic lupus erythematosus - relationship with disease activity and renal involvement.

Oelzner P, Deliyska B, Fünfstück R, Hein G, Herrmann D, Stein G.

Clin Rheumatol. 2003 Oct;22(4-5):271-8.

PMID:
14576989
7.

Type I interferon-mediated skewing of the serotonin synthesis is associated with severe disease in systemic lupus erythematosus.

Lood C, Tydén H, Gullstrand B, Klint C, Wenglén C, Nielsen CT, Heegaard NH, Jönsen A, Kahn R, Bengtsson AA.

PLoS One. 2015 Apr 21;10(4):e0125109. doi: 10.1371/journal.pone.0125109. eCollection 2015.

8.

Juvenile-onset systemic lupus erythematosus: different clinical and serological pattern than adult-onset systemic lupus erythematosus.

Hoffman IE, Lauwerys BR, De Keyser F, Huizinga TW, Isenberg D, Cebecauer L, Dehoorne J, Joos R, Hendrickx G, Houssiau F, Elewaut D.

Ann Rheum Dis. 2009 Mar;68(3):412-5. doi: 10.1136/ard.2008.094813. Epub 2008 Oct 17.

PMID:
18930995
9.

The receptor for type I IFNs is highly expressed on peripheral blood B cells and monocytes and mediates a distinct profile of differentiation and activation of these cells.

Pogue SL, Preston BT, Stalder J, Bebbington CR, Cardarelli PM.

J Interferon Cytokine Res. 2004 Feb;24(2):131-9.

PMID:
14980077
10.

Association of anti-nucleoprotein autoantibodies with upregulation of Type I interferon-inducible gene transcripts and dendritic cell maturation in systemic lupus erythematosus.

Zhuang H, Narain S, Sobel E, Lee PY, Nacionales DC, Kelly KM, Richards HB, Segal M, Stewart C, Satoh M, Reeves WH.

Clin Immunol. 2005 Dec;117(3):238-50. Epub 2005 Aug 25.

PMID:
16126005
11.

Clinical and serological manifestations associated with interferon-α levels in childhood-onset systemic lupus erythematosus.

Postal M, Sinicato NA, Peliçari KO, Marini R, Lavras Costallat LT, Appenzeller S.

Clinics (Sao Paulo). 2012;67(2):157-62.

12.

High mobility group box 1 (HMGB1) and anti-HMGB1 antibodies and their relation to disease characteristics in systemic lupus erythematosus.

Abdulahad DA, Westra J, Bijzet J, Limburg PC, Kallenberg CG, Bijl M.

Arthritis Res Ther. 2011 May 6;13(3):R71. doi: 10.1186/ar3332.

13.

Baseline predictors of systemic lupus erythematosus flares: data from the combined placebo groups in the phase III belimumab trials.

Petri MA, van Vollenhoven RF, Buyon J, Levy RA, Navarra SV, Cervera R, Zhong ZJ, Freimuth WW; BLISS-52 and BLISS-76 Study Groups.

Arthritis Rheum. 2013 Aug;65(8):2143-53. doi: 10.1002/art.37995.

14.

Interferon-α-induced B-lymphocyte stimulator expression and mobilization in healthy and systemic lupus erthymatosus monocytes.

López P, Scheel-Toellner D, Rodríguez-Carrio J, Caminal-Montero L, Gordon C, Suárez A.

Rheumatology (Oxford). 2014 Dec;53(12):2249-58. doi: 10.1093/rheumatology/keu249. Epub 2014 Jun 18.

PMID:
24942493
15.

Association of increased interferon-inducible gene expression with disease activity and lupus nephritis in patients with systemic lupus erythematosus.

Feng X, Wu H, Grossman JM, Hanvivadhanakul P, FitzGerald JD, Park GS, Dong X, Chen W, Kim MH, Weng HH, Furst DE, Gorn A, McMahon M, Taylor M, Brahn E, Hahn BH, Tsao BP.

Arthritis Rheum. 2006 Sep;54(9):2951-62.

16.

Monocyte CD64 expression as a novel biomarker for the disease activity of systemic lupus erythematosus.

Kikuchi-Taura A, Yura A, Tsuji S, Ohshima S, Kitatoube A, Shimizu T, Nii T, Katayama M, Teshigawara S, Yoshimura M, Kudo-Tanaka E, Harada Y, Matsushita M, Hashimoto J, Saeki Y.

Lupus. 2015 Sep;24(10):1076-80. doi: 10.1177/0961203315579093. Epub 2015 Mar 24.

PMID:
25804673
17.

Serum free light chains, interferon-alpha, and interleukins in systemic lupus erythematosus.

Jolly M, Francis S, Aggarwal R, Mikolaitis RA, Niewold TB, Chubinskaya S, Block JA, Scanzello C, Sequeira W.

Lupus. 2014 Aug;23(9):881-8. doi: 10.1177/0961203314530793. Epub 2014 Apr 30.

PMID:
24786785
18.
19.

Anti-C1q antibodies in systemic lupus erythematosus.

Orbai AM, Truedsson L, Sturfelt G, Nived O, Fang H, Alarcón GS, Gordon C, Merrill J, Fortin PR, Bruce IN, Isenberg DA, Wallace DJ, Ramsey-Goldman R, Bae SC, Hanly JG, Sanchez-Guerrero J, Clarke AE, Aranow CB, Manzi S, Urowitz MB, Gladman DD, Kalunian KC, Costner MI, Werth VP, Zoma A, Bernatsky S, Ruiz-Irastorza G, Khamashta MA, Jacobsen S, Buyon JP, Maddison P, Dooley MA, Van Vollenhoven RF, Ginzler E, Stoll T, Peschken C, Jorizzo JL, Callen JP, Lim SS, Fessler BJ, Inanc M, Kamen DL, Rahman A, Steinsson K, Franks AG Jr, Sigler L, Hameed S, Pham N, Brey R, Weisman MH, McGwin G Jr, Magder LS, Petri M.

Lupus. 2015 Jan;24(1):42-9. doi: 10.1177/0961203314547791. Epub 2014 Aug 14.

20.

Anti-C1q antibodies have higher correlation with flares of lupus nephritis than other serum markers.

Akhter E, Burlingame RW, Seaman AL, Magder L, Petri M.

Lupus. 2011 Oct;20(12):1267-74. doi: 10.1177/0961203311411597. Epub 2011 Aug 3.

PMID:
21813587

Supplemental Content

Support Center